A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
Gemfibrozil-statin combination therapy is a well-known risk factor for myopathy and rhabdomyolysis. Cerivastatin is a currently available statin with dual elimination; it is therefore expected to cause less drug-drug interaction. This case is the second reported case with severe rhabdomyolysis caused by cerivastatin-gemfibrozil combination. Moreover, in this case, the rhabdomyolysis was more severe and caused severe renal failure and death. The authors discuss how these drugs cause rhabdomyolysis and how rhabdomyolysis can cause renal failure.
Ozdemir
O
O
Department of Cardiology, Türkiye Yüksek Ihtisas Hastanesi, Ankara, Turkey. dr.ozdemir@yahoo.com
Boran
M
M
Gökçe
V
V
Uzun
Y
Y
Koçak
B
B
Korkmaz
S
S
D003920:Diabetes Mellitus / Q000188:drug therapy; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D017809:Fatal Outcome; D015248:Gemfibrozil / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000628:therapy; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000150:complications / Q000628:therapy
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011725:Pyridines; C086276:cerivastatin; D015248:Gemfibrozil